Keywords: oncogenex, in-licenses, hsp70, cancer, drug, candidates, vancouver
OncoGenex in-licenses Hsp70 cancer drug candidates
Article | 16 May 2005
Vancouver, Canada-headquartered OncoGenex Technologies has in-licensed the rights to inhibitors of heat-shock protein 27 from the University of British Columbia, Canada.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
